Protalix is a biopharmaceutical company that is revolutionizing the development and manufacturing of recombinant therapeutic proteins.
Protalix Biotherapeutics has raised €36M across 1 funding round, most recently a round in Dec 2020. Based in Carmiel, Israel; founded 1994; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-12-03 | Other | €36M |
| — |
| View deal → |
